Executive Chairman, Chief Executive Officer and Co-Founder
Chief Executive Officer, Co-Founder
Founder & Chairman,
Field Trip Ventures
Matthew W. Johnson, Ph.D.
Professor of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
Kelly Willenberg & Associates
Mike “Zappy” Zapolin
“Lamar Odom: Reborn” 2020, “The Reality Of Truth” 2017
About the Summit
After spending decades in the shadows, psychedelics and empathogens have slowly reemerged as an effective treatment option for a wide variety of behavioral health issues including depression, anxiety, PTSD, chronic inflammation and addiction. With the cannabis legalization movement creeping towards maturity, American society has moved towards a more open-minded approach when it comes to this family of drugs that remain legally classified as a Schedule I substance under the Controlled Substances Act as the potential to provide relief to millions of afflicted people is an opportunity to large to ignore.
With a regulatory pathway already established, the next barrier is funding, but in order to drive greater investment, all interested parties must first understand the opportunity; from size and scope to models and applications.
Momentum’s Psychedelic Opportunity Summit has been designed to provide attendees with the scientific, medical, regulatory, economic, cultural and entrepreneurial knowledge need to determine an investment strategy. Whether you’re an investor, an insurance company, a pharmaceutical company, hospital system or entrepreneur, there is opportunity in the use of psychedelics to address a range of ailments including depression, anxiety, addiction, PTSD, chronic inflammation and alzheimers.
Attend this conference you will gain real world knowledge from industry veterans, experts, medical professionals and entrepreneurs including:
The Current State of Psychedelic Affairs, Research, Trials, and Conclusions
The Legal and Regulatory Environment for Psychedelics
Effectively Running Clinical Trials with a Psychedelic and Therapy Support
Current and Potential Future Innovations in Mental Health Care
Theoretical Incorporation of Psychedelic Treatment Into the US Payer Ecosystem
The Founder's Mission
The Psychedelic Opportunity Summit was founded by Momentum’s CEO Ben Greenzweig who’s passionate purpose is mental health. While developing conferences has been his speciality for more than two decades, as an open depressive who blogs and talks openly about his battles in hope of breaking down the stigma, Ben’s curiosity about his disease led him on a journey to discover the therapeutic potential of psychedelics and empathogens. It is from this passion that forged his determination to do his part to support the responsible growth of this industry and provide a way to help many, like him, who suffer.
While Momentum Events support research on therapeutic applications of psychedelics, Momentum by no means promotes or condones the use of any illegal substance. Information conveyed during the conference is for educational purposes only, and is not intended to be used as treatment advice.
STATEMENT ON MEDICAL ADVICE: THE CONFERENCE, EVENT WEBSITE OR SPEAKERS MAY OFFER HEALTH, FITNESS, NUTRITIONAL, AND OTHER SUCH INFORMATION, BUT SUCH INFORMATION IS DESIGNED FOR EDUCATIONAL, AND INFORMATIONAL PURPOSES ONLY. THE INFORMATION CONTAINED ON THE SITE DOES NOT AND IS NOT INTENDED TO CONVEY MEDICAL ADVICE AND DOES NOT CONSTITUTE THE PRACTICE OF MEDICINE. YOU SHOULD NOT RELY ON THIS INFORMATION AS A SUBSTITUTE FOR, NOR DOES IT REPLACE PROFESSIONAL MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT. WE ARE NOT RESPONSIBLE FOR ANY ACTIONS OR INACTION ON A USER’S PART BASED ON THE INFORMATION THAT IS PRESENTED ON THE SITE.
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.